These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 26925650)
1. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran. Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650 [TBL] [Abstract][Full Text] [Related]
2. Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. Gorukmez O; Yakut T; Gorukmez O; Sag SO; Karkucak M; Kanat O Asian Pac J Cancer Prev; 2016; 17(3):1175-9. PubMed ID: 27039744 [TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. Zhang X; Wang Y; Gao N; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565 [TBL] [Abstract][Full Text] [Related]
4. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran. Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109 [TBL] [Abstract][Full Text] [Related]
5. RAS status in Korean patients with stage III and IV colorectal cancer. Lee WS; Lee JN; Baek JH; Park YH Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687 [TBL] [Abstract][Full Text] [Related]
6. Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. Payandeh M; Shazad B; Sadeghi M; Shahbazi M Asian Pac J Cancer Prev; 2016; 17(4):1729-32. PubMed ID: 27221845 [TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644 [TBL] [Abstract][Full Text] [Related]
8. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. Kim JH; Bae JM; Cho NY; Kang GH Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113 [TBL] [Abstract][Full Text] [Related]
9. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component. Li X; Sun K; Liao X; Gao H; Zhu H; Xu R BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877 [TBL] [Abstract][Full Text] [Related]
10. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750 [TBL] [Abstract][Full Text] [Related]
11. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692 [TBL] [Abstract][Full Text] [Related]
12. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889 [TBL] [Abstract][Full Text] [Related]
13. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517 [TBL] [Abstract][Full Text] [Related]
14. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270 [TBL] [Abstract][Full Text] [Related]
15. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874 [TBL] [Abstract][Full Text] [Related]
17. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028 [TBL] [Abstract][Full Text] [Related]
18. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Bagadi SB; Sanghvi M; Nair SB; Das BR Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190 [TBL] [Abstract][Full Text] [Related]
19. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
20. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]